Richard Clark, MA, MD, MRCP, FRCPath, is a Professor of Haematology and Consultant Haematologist, Royal Liverpool University Hospital, Liverpool, UK. Prof. Clark previously co-initiated the Cardiff research programme into myelodysplastic syndromes. He is a member of various societies, namely the National Cancer Research Institute, the European Hematology Association, the American Society of Hematology, and the British Society for Hematology.
Speaking on chronic myeloid leukemia therapeutics
Prof. Clark’s research interests lie in developing novel techniques to treat chronic myeloid leukemia (CML). His team has been extensively involved in various clinical trials of tyrosine kinase inhibitors, mainly imatinib as well as the pivotal clinical trial of CML vaccinations with BCR-ABL peptides.